Drug-Eluting Balloon Catheters

[Through the course of researching and analyzing coronary artery disease treatments, technologies and markets for our May 2009 worldwide coronary stents market report, we have compiled data on the ancillary market of drug-eluting balloons, which we synopsize below.]

Drug-Eluting Balloons

A handful of companies are developing drug-coated balloon catheters as an alternative to balloon angioplasty and stenting and for those who would not benefit from PCI, such as those in whom antiplatelet therapy is neither recommended nor desired. 

The concept behind the technology is based on the assumption that delivering a rapid release of drugs into the arterial tissue is more effective than the gradual release of drugs, as seen with drug-eluting stents. Another side benefit of the technology would be significant cost-savings. Angioplasty balloons currently used typically cost roughly $400 each.


Technologies/approaches being developed by specific companies include:

  • drug-coated angioplasty catheters for coronary and peripheral applications
  • development of paclitaxel-coated angioplasty catheter
  • coating standard angioplasty balloons with paclitaxel
  • bioabsorbable coating on balloon drug-eluting balloon catheter
  • mix of paclitaxel and hydrophilic spacer on balloon surface
  • paclitaxel-eluting balloon catheter for in-stent restenosis, bifurcated lesions, small diameter lesions, etc.
  • polymer-based drug delivery on balloon catheter
  • paclitaxel-eluting balloon catheter with controlled drug release for coronary and peripheral applications
  • drug-eluting balloon catheter with surface that penetrates, splits stenosis to facilitate drug delivery


 Developers of Paclitaxel-Eluting Balloon Catheters

See report #C245 for table of companies with products in development

Source:  MedMarket Diligence report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." May 2009. 

Purchase for download:  Report #C245, "Worldwide Coronary Stents 2009, PDF" — $2,850.00
themesmedia/tab_blue_button_add.gif  themesmedia/tab_blue_button_view.gif

11 thoughts on “Drug-Eluting Balloon Catheters”

  1. Now first Data from ELUTAX:

    The IASIS-CE Register is a project for registering the use of ELUTAX on the coronary vessels and in-stent restenosis

    30 Patients in instent Restenosis

    6 months angiographic follow-up
    0% Restenosis

    Also Elutax release more than 75% of drug after first inflation!

  2. The numbers don't look bad, but I will save my opinion until time will tell what the long term effect are or maybe unforseen secondary effects. I have learnt in my experience that drugs need to be tested a lot before you can make a valid statement about efficiency and effects.
    Drug Treatments

  3. Many of the same companies developing catheter-based technologies for cardiology applications are developing catheter technologies for urology. Similarly, stent technologies developed for cardiac applications are being leveraged for urology. Put simply, blood vessels and ducts of any kind share a common potential for technology development.

Leave a Reply